Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 7Other solid neoplasm 3Gastrointestinal 3Dermatologic 3Thoracic 2Breast 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

KRAS Mutant Non-Small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × mirdametinib × Thoracic × Clear all
NCT02022982 2024-03-19

PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors

Dana-Farber Cancer Institute

Phase 1 Completed
60 enrolled
Other solid neoplasmThoracic

KRAS Mutant Non-Small Cell Lung Cancer

NCT00174369 2009-03-17

MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer

Pfizer

Phase 2 Terminated
34 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡